Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
123.505 USD -0.20 ( 0.17%)
Last update at 2026-11-11T20:54:00Z
VOLUME
996030
Market Cap
5227.55M
P/E
88.04

Momentum Score

…

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
123.25
Low
130.36
High
52 Week Price Range
98.27
Low
176.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
123.71
Dividend Yield
-
Revenue TTM
1029.70M
Revenue Per Share
26.45
Gross Profit TTM
458.68M
Debt / Equity
0.26
ROE
5.11%
Net Debt
-39.26M
ROCE
5.71%
Diluted EPS TTM
1.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 69.64M 79.07M 83.75M 87.16M 56.17M
Net income 53.83M 64.09M 72.88M 74.05M 50.33M
Selling general administrative 195.66M 175.94M 161.47M 158.90M 129.16M
Gross profit 407.81M 421.55M 399.90M 378.47M 300.33M
Reconciled depreciation 61.93M 55.56M 47.22M 53.16M 43.39M
Ebit 91.11M 124.29M 123.31M 103.08M 100.22M
Ebitda 153.05M 179.86M 169.92M 164.94M 143.62M
Depreciation and amortization 61.93M 55.56M 46.61M 61.86M 43.39M
Non operating income net other - - - -0.30M -0.49M
Operating income 116.66M 110.58M 110.50M 103.08M 100.22M
Other operating expenses 863.94M 838.66M 771.17M 753.44M 624.72M
Interest expense 21.47M 31.49M 25.82M -15.62M -7.39M
Tax provision 15.81M 14.98M 11.31M 13.11M 5.84M
Net interest income -21.47M -31.49M -25.59M -15.62M -7.39M
Non recurring - - - 4.38M 18.02M
Income tax expense 15.81M 14.98M 10.87M 13.11M 5.84M
Total revenue 980.60M 949.25M 881.66M 860.90M 706.79M
Total operating expenses 291.14M 310.96M 289.40M 271.01M 218.25M
Cost of revenue 572.79M 527.70M 481.76M 482.43M 406.46M
Total other income expense net -47.02M -31.52M -26.75M -15.92M -44.05M
Net income from continuing ops 53.83M 64.09M 75.63M 74.05M 50.33M
Net income applicable to common shares - - - 74.05M 50.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1807.11M 1388.51M 1226.06M 1241.21M 1227.88M
Intangible assets 180.78M 185.84M 145.02M 175.77M 220.99M
Other current assets 28.57M 24.03M 21.46M 14.72M 15.16M
Total liab 492.82M 642.81M 552.60M 663.63M 706.59M
Total stockholder equity 1314.29M 745.70M 673.46M 577.59M 521.29M
Deferred long term liab - - - 17.19M 33.74M
Other current liab 62.67M 53.86M 62.55M 76.37M 103.33M
Common stock 423.86M 423.86M 423.86M 423.86M 423.86M
Capital stock 423.86M 423.86M 423.86M 423.86M 423.86M
Retained earnings 321.38M 267.55M 203.46M 130.58M 56.53M
Other liab - - - 22.98M 47.59M
Good will 647.35M 584.10M 484.51M 478.90M 479.50M
Other assets - - - 19.53M 17.79M
Cash 380.87M 113.99M 105.05M 100.11M 117.39M
Total current liabilities 212.37M 167.79M 139.18M 164.52M 183.94M
Current deferred revenue - 5.71M 5.55M 8.13M 7.00M
Net debt -39.26M 357.01M 299.51M 376.17M 362.76M
Short term debt 48.98M 15.33M 13.88M 4.80M 5.10M
Short long term debt 38.29M 4.69M 4.97M 4.80M 5.10M
Short long term debt total 341.61M 471.00M 404.56M 476.27M 480.16M
Other stockholder equity 572.06M 84.21M 70.18M 55.16M 53.77M
Property plant equipment - - - 103.19M 135.78M
Total current assets 782.60M 433.65M 415.30M 420.52M 373.82M
Net tangible assets - - - -77.08M -179.20M
Net receivables 184.88M 151.03M 139.41M 137.70M 115.62M
Long term debt 212.54M 411.95M 349.40M 430.66M 429.36M
Inventory 188.28M 144.61M 149.37M 168.00M 125.66M
Accounts payable 94.86M 76.89M 57.20M 75.22M 68.51M
Accumulated other comprehensive income -3.00M -29.92M -24.04M -32.01M -12.87M
Common stock total equity - - - 423.86M 423.86M
Retained earnings total equity - - - 130.58M 56.53M
Non currrent assets other 8.81M 5.99M 5.62M 4.41M 17.79M
Non current assets total 1024.51M 954.86M 810.76M 820.69M 854.06M
Capital lease obligations 51.08M 54.36M 50.19M 53.92M 58.94M
Long term debt total - - - 430.66M 429.36M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -208.19M -19.89M -42.54M -306.70M
Change to liabilities - - - 30.82M 24.38M
Total cashflows from investing activities -74.32M -208.19M -19.89M -42.54M -306.70M
Net borrowings -282.92M 66.93M -86.55M 8.42M 247.62M
Total cash from financing activities 276.33M 56.94M -97.85M -60.15M 204.75M
Change to operating activities - - - -3.77M 17.42M
Net income 53.83M 64.09M 72.88M 74.05M 50.33M
Change in cash 266.88M 8.94M 4.95M -17.29M -7.66M
Begin period cash flow 113.99M 105.05M 100.11M 117.39M 125.05M
End period cash flow 380.87M 113.99M 105.05M 100.11M 117.39M
Total cash from operating activities 64.06M 158.51M 120.08M 90.78M 94.62M
Issuance of capital stock 614.39M 0.00M 0.00M - -
Depreciation 61.93M 55.56M 46.61M 53.16M 43.39M
Other cashflows from investing activities 5.60M 0.17M 0.07M -22.90M -2.00M
Change to inventory -36.10M 4.78M 11.37M -48.55M -19.08M
Change to account receivables -27.27M -6.19M -0.13M -23.25M -25.36M
Sale purchase of stock -39.28M -9.71M -10.56M -10.00M 0.00M
Other cashflows from financing activities -11.15M -9.99M -0.74M 8.88M 237.13M
Change to netincome - - - 7.52M 27.91M
Capital expenditures 15.63M 17.16M 19.96M 19.64M 19.98M
Change receivables - - - -23.25M -25.36M
Cash flows other operating - - - -2.98M -5.54M
Cash and cash equivalents changes - - - -11.92M -7.33M
Change in working capital -75.13M 18.92M -21.33M -44.74M -27.01M
Stock based compensation 29.54M 23.31M 25.59M 23.11M 25.61M
Other non cash items 2.74M 12.55M 11.05M 3.85M 6.25M
Free cash flow 48.43M 141.35M 100.11M 71.14M 74.65M

Peer Comparison*

Sector: Technology Industry: Scientific & Technical Instruments

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NOVT
Novanta Inc
-0.20
0.17%
123.50 88.04 8.39 5.08 3.27 4.72 26.77
KYCCF
Keyence
-1.77
0.38%
470.00 41.66 38.76 0.11 5.69 0.10 0.19
COHR
Coherent Corp
19.90
9.27%
234.56 333.78 46.73 10.24 7.63 10.78 62.92
GRMN
Garmin Ltd
-
-%
293.93 28.91 24.45 7.01 5.99 6.72 22.32
KEYS
Keysight Technologies Inc
14.18
4.87%
305.64 42.58 20.00 8.11 8.16 8.17 28.06

Profile*

Novanta Inc

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

125 Middlesex Turnpike, Bedford, MA, United States, 01730

781 266 5700

3000

Name Title Year Born
Mr. Matthijs Glastra CEO & Chairman 1969
Mr. Robert J. Buckley Chief Financial Officer 1974
Mr. Brian S. Young Chief HR Officer 1969
Mr. Peter L. Chang Corp. Controller & Chief Accounting Officer 1965
Ms. Sarah Betadam Chief Information Officer NA
Ms. Michele Davis Michele Welsh Gen. Counsel & Corp. Sec. NA
Mr. Charlie Webster Exec. VP of Novanta Growth System & Global Supply Chain NA
Mr. Chuck Ravetto Group Pres of Automation Enabling Technologies Group NA
Mr. Heinrich Dreyer Group Pres of Vision NA
Mr. Ray Nash Corp. Fin. Leader NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…